eGenesis gains $38M to use CRISPR to help tame pig organs for transplants
Read: eGenesis gains $38M to use CRISPR to help tame pig organs for transplants (FierceBiotech, 3/16/17)
Mission Statement
eGenesis is a life sciences company focused on leveraging gene editing technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.
Contact Us
eGenesis
300 Technology Square, Suite 301
Cambridge, MA 02139
info@egenesisbio.com
Latest News
- eGenesis Appoints Industry Veteran Paul Sekhri as President and Chief Executive Officer
- Julie Sunderland, CEO at eGenesis, explains a gene editing platform for the development of human-compatible organs, tissues and cells
- eGenesis Appoints William Westlin, Ph.D., as Executive Vice President of Research & Development